Leonard G. Gomella, MD
Genetic testing to identify men with prostate cancer who have BRCA1/2
mutations and other abnormalities could provide insight as to whether they may develop aggressive disease and early metastasis, said Leonard G. Gomella, MD, FACS.
This advancement in the field, as well as other assays to determine disease characteristics, is changing the space of prostate cancer for the better, continued Gomella.
... to read the full story